CJC-1295 research guide for Agigea. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Agigea searching for CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. What this means for Agigea researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those verification methods are within reach of all serious researchers. A properly operating CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. This guide walks Agigea researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Agigea studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Buying CJC-1295: Quality Markers to Look For
The most consistent path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums track vendor quality over time that are more accurate than commercial vendor claims. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are below the threshold for research use. For Agigea researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before committing to research quantities is what experienced peptide researchers consistently do. For Agigea researchers making a first CJC-1295 purchase: verify the vendor against this framework, start with a modest quantity, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Agigea
COA-verified · International tracking · Research grade
CJC-1295 operates beyond the scope of approved drug regulation — researchers should understand that the safety data available for CJC-1295 is based on research literature rather than clinical trials. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with bac water. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no discount compensates for this missing data. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not approved for human use and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
